Make an enquiry
Refer a patient
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor

Basket – Solid tumours

Basket – Solid tumours
2025-06-13T00:00:00.000+10:00
Ongoing

GB268-001

GB268-001
Basket

A Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Patients with Advanced Solid Tumors

A Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Patients with Advanced Solid Tumors

Trial overview

Clinical Area

Medical Oncology

Disease

Basket - Solid tumours

Disease site

Basket

Study Phase

I

Trial Identifiers

Registration number: NCT06934616

https://clinicaltrials.gov/study/NCT06934616

GenesisCare Location(s)
Principal Investigator(s)
Medical Oncologist

Dr Adrian Lee

BSc (Med) MBBS (Hons) FRACP PhD

Dr Adrian Lee
location pin icon

North Shore

View Profile
Profile Image - Dr Adrian Lee

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.


 

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.